• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对《mTORC1/2抑制剂vistusertib联合氟维司群在体外和体内靶向雌激素受体阳性内分泌耐药乳腺癌》的更正

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

作者信息

Pancholi Sunil, Leal Mariana Ferreira, Ribas Ricardo, Simigdala Nikiana, Schuster Eugene, Chateau-Joubert Sophie, Zabaglo Lila, Hills Margaret, Dodson Andrew, Gao Qiong, Johnston Stephen R, Dowsett Mitch, Cosulich Sabina C, Marangoni Elisabetta, Martin Lesley-Ann

机构信息

Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK.

BioPole Alfort, Ecole Nationale Veterinaire d'Alford, Maisons Alfort, France.

出版信息

Breast Cancer Res. 2020 Jan 31;22(1):14. doi: 10.1186/s13058-020-1254-5.

DOI:10.1186/s13058-020-1254-5
PMID:32005287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6993431/
Abstract

After publication of the original article [1], we were notified that an author's surname has been erroneously spelled. Elisabetta Maragoni's family name should be replaced with Marangoni.

摘要

在原文章[1]发表后，我们收到通知，一位作者的姓氏拼写有误。伊丽莎白塔·马拉戈尼（Elisabetta Maragoni）的姓氏应改为马兰戈尼（Marangoni）。

相似文献

1
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.对《mTORC1/2抑制剂vistusertib联合氟维司群在体外和体内靶向雌激素受体阳性内分泌耐药乳腺癌》的更正
Breast Cancer Res. 2020 Jan 31;22(1):14. doi: 10.1186/s13058-020-1254-5.
2
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.mTORC1/2 抑制剂 vistusertib 联合氟维司群在体外和体内靶向治疗雌激素受体阳性内分泌耐药性乳腺癌。
Breast Cancer Res. 2019 Dec 4;21(1):135. doi: 10.1186/s13058-019-1222-0.
3
Correction to: Occurrence and seasonal variation of human Plasmodium infection in Punjab Province, Pakistan.对《巴基斯坦旁遮普省人类疟原虫感染的发生情况及季节变化》的更正
BMC Infect Dis. 2020 Jan 8;20(1):25. doi: 10.1186/s12879-020-4767-8.
4
Correction to: Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events.对以下内容的更正：通过流式细胞术和细胞内细胞因子染色测量巨细胞病毒（CMV）特异性CD4 +和CD8 + T细胞免疫以预测具有临床意义的CMV事件的新型检测方法的临床经验。
BMC Infect Dis. 2020 Feb 11;20(1):122. doi: 10.1186/s12879-020-4848-8.
5
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.SNAI2 上调与氟维司群耐药乳腺癌细胞的侵袭表型相关，是雌激素受体阳性转移性乳腺癌内分泌治疗反应不良的标志。
Breast Cancer Res. 2018 Jun 19;20(1):60. doi: 10.1186/s13058-018-0988-9.
6
Correction to: Recruiting the microcirculation in septic shock.对《脓毒症休克中微循环的募集》的更正
Ann Intensive Care. 2019 Sep 24;9(1):107. doi: 10.1186/s13613-019-0581-0.
7
Correction to: Factors associated with acute kidney injury in acute respiratory distress syndrome.对《急性呼吸窘迫综合征中与急性肾损伤相关的因素》的更正
Ann Intensive Care. 2019 Jul 23;9(1):84. doi: 10.1186/s13613-019-0558-z.
8
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.在绝经后激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者中，比较布帕利西布联合氟维司群与安慰剂联合氟维司群的疗效（BELLE-2）：一项随机、双盲、安慰剂对照的3期试验。
Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.
9
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.在 PALOMA-3 研究中，内分泌耐药的激素受体阳性/人表皮生长因子受体 2 阴性转移性乳腺癌女性中，帕博西利联合氟维司群延长获益的预测因素。
Eur J Cancer. 2018 Nov;104:21-31. doi: 10.1016/j.ejca.2018.08.011. Epub 2018 Oct 8.
10
Correction to: HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.对《丙型肝炎病毒感染个体合并症和多重合并症的患病率更高：一项回顾性队列研究》的更正
BMC Infect Dis. 2019 Oct 24;19(1):889. doi: 10.1186/s12879-019-4579-x.

本文引用的文献

1
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.mTORC1/2 抑制剂 vistusertib 联合氟维司群在体外和体内靶向治疗雌激素受体阳性内分泌耐药性乳腺癌。
Breast Cancer Res. 2019 Dec 4;21(1):135. doi: 10.1186/s13058-019-1222-0.